Faron Pharmaceuticals Oy (OTCPK:FPHAF)
$ 3.3 0 (0%) Market Cap: 215.14 Mil Enterprise Value: 221.88 Mil PE Ratio: 0 PB Ratio: 150.00 GF Score: 39/100

Faron Pharmaceuticals Oy at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 08:00PM GMT
Josh Bowers JPMorgan;Analyst

Good afternoon, everyone. Welcome to the final day of the JPMorgan conference. I'm Josh Bowers from the London healthcare team.

It's my absolute pleasure today to welcome Dr. Markku to present to you today. We'll have 20, 25 minutes, and then we'll open up to some questions. And then he'll stick around afterwards if you have any follow-ups.

And with that, I'll hand it over to you, Markku.

Markku Jalkanen Faron Pharmaceuticals Oy;CEO;Founder

&

Thank you, Joshua. I understand that this is really a privilege. So I would really thank also JPMorgan management, really, giving this opportunity to talk about Farron.

As you may already notice, we are a dualistic company, both in London, AIM, and then Helsinki First North. And obviously, I want to show this disclaimer really. Because I'm going to say something about the future of the company as well.

So I believe that we are the world leader at the moment in reprogramming myeloid cells. Why we want to do that? They are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot